Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > April 2013 - Volume 17 - Issue > 2012 Updated Consensus Guidelines for the Management of Abno...
Text sizing:
A
A
A
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0b013e318287d329
Original Article

2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Massad, L. Stewart MD; Einstein, Mark H. MD; Huh, Warner K. MD; Katki, Hormuzd A. PhD; Kinney, Walter K. MD; Schiffman, Mark MD; Solomon, Diane MD; Wentzensen, Nicolas MD; Lawson, Herschel W. MD; for the 2012 ASCCP Consensus Guidelines Conference

Erratum

Erratum

Because of an error, Fig. 15 in the “2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors” is incorrect. The correct algorithm for the Management of Women Ages 21-24 with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia-grade 1 (CIN1) follows.

Journal of Lower Genital Tract Disease. 17(3):367, July 2013.

Collapse Box

Abstract

ABSTRACT: A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14–15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group’s goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) following adoption of cervical cancer screening guidelines incorporating longer screening intervals and co-testing. In addition to literature review, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk after abnormal tests. Where data were available, guidelines prescribed similar management for women with similar risks for CIN 3, AIS, and cancer. Most prior guidelines were reaffirmed. Examples of updates include: Human papillomavirus–negative atypical squamous cells of undetermined significance results are followed with co-testing at 3 years before return to routine screening and are not sufficient for exiting women from screening at age 65 years; women aged 21–24 years need less invasive management, especially for minor abnormalities; postcolposcopy management strategies incorporate co-testing; endocervical sampling reported as CIN 1 should be managed as CIN 1; unsatisfactory cytology should be repeated in most circumstances, even when HPV results from co-testing are known, while most cases of negative cytology with absent or insufficient endocervical cells or transformation zone component can be managed without intensive follow-up.

©2013The American Society for Colposcopy and Cervical Pathology

Login

Article Tools

Share